201 related articles for article (PubMed ID: 29781033)
21. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
22. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
[TBL] [Abstract][Full Text] [Related]
23. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
24. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
[TBL] [Abstract][Full Text] [Related]
25. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
Nagano H; Tomimaru Y; Eguchi H; Hama N; Wada H; Kawamoto K; Kobayashi S; Mori M; Doki Y
Int J Oncol; 2013 Oct; 43(4):1066-72. PubMed ID: 23900458
[TBL] [Abstract][Full Text] [Related]
27. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines.
Chen T; Luo J; Gu Y; Huang J; Luo Q; Yang Y
Thorac Cancer; 2019 Apr; 10(4):930-941. PubMed ID: 30883029
[TBL] [Abstract][Full Text] [Related]
29. Analysis of exosomal circRNAs upon irradiation in pancreatic cancer cell repopulation.
Chen YY; Jiang MJ; Tian L
BMC Med Genomics; 2020 Jul; 13(1):107. PubMed ID: 32727565
[TBL] [Abstract][Full Text] [Related]
30. Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
Zhao C; Gao Y; Guo R; Li H; Yang B
Invest New Drugs; 2020 Oct; 38(5):1227-1235. PubMed ID: 31823158
[TBL] [Abstract][Full Text] [Related]
31. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
32. High-throughput sequencing of circRNAs reveals novel insights into mechanisms of nigericin in pancreatic cancer.
Xu Z; Shen J; Hua S; Wan D; Chen Q; Han Y; Ren R; Liu F; Du Z; Guo X; Shi J; Zhi Q
BMC Genomics; 2019 Sep; 20(1):716. PubMed ID: 31533620
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
34. The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway.
Han L; Jiang J; Ma Q; Wu Z; Wang Z
Int J Oncol; 2018 Jun; 52(6):2101-2109. PubMed ID: 29620188
[TBL] [Abstract][Full Text] [Related]
35. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive expression profiles and bioinformatics analysis reveal special circular RNA expression and potential predictability in the peripheral blood of humans with idiopathic membranous nephropathy.
Jin X; Deng B; Ye K; Ye D; Huang Y; Chen X; Yang Z; Chen Y
Mol Med Rep; 2019 Nov; 20(5):4125-4139. PubMed ID: 31545426
[TBL] [Abstract][Full Text] [Related]
37. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
Chen ZW; Hu JF; Wang ZW; Liao CY; Kang FP; Lin CF; Huang Y; Huang L; Tian YF; Chen S
J Exp Clin Cancer Res; 2022 Apr; 41(1):153. PubMed ID: 35459186
[TBL] [Abstract][Full Text] [Related]
38. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
Hu W; Liu Q; Pan J; Sui Z
Biomed Pharmacother; 2018 Sep; 105():887-898. PubMed ID: 30021382
[TBL] [Abstract][Full Text] [Related]
39. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
40. Mobius strip in pancreatic cancer: biogenesis, function and clinical significance of circular RNAs.
Zhao B; Li Z; Qin C; Li T; Wang Y; Cao H; Yang X; Wang W
Cell Mol Life Sci; 2021 Sep; 78(17-18):6201-6213. PubMed ID: 34342664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
